Background. Nonalcoholic fatty liver disease (NAFLD) is commonly observed in patients
with type 2 diabetes (T2D). Semaglutide, a glucagon-like peptide 1 receptor agonist, may …

Abstract Background and Aim This study aimed to clarify the efficacy and safety of oral
semaglutide treatment in patients with non‐alcoholic fatty liver disease (NAFLD) …

Aim This systematic review and meta-analysis was conducted to evaluate the efficacy and
safety of 24 weeks of semaglutide treatment in patients with non-alcoholic fatty liver disease …

BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic
liver disease. The prevalence and disease burden of NAFLD are projected to exponentially …

Background Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease
(NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes …

Background Oral semaglutide is the first glucagon-like peptide-1 receptor agonist (GLP-
1RA) designed for oral administration; it offers a promising opportunity to facilitate an early …

Background Glucagon‐like peptide‐1 receptor agonists may be a treatment option in
patients with non‐alcoholic fatty liver disease (NAFLD). Aims To investigate the effects of …

Purpose The aim of this study was to evaluate changes in body weight, liver weight, blood
glucose, liver injury markers, pro-inflammatory factors and oxidative stress marker levels in …

Semaglutide, a glucagon-like peptide-1 receptor agonist, is an antidiabetic medication that
has recently been approved for the treatment of obesity as well. Semaglutide is postulated to …

Background: Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their …